These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 34418585)
41. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma. Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708 [TBL] [Abstract][Full Text] [Related]
43. Histopathology of hepatocellular carcinoma. Paradis V Recent Results Cancer Res; 2013; 190():21-32. PubMed ID: 22941011 [TBL] [Abstract][Full Text] [Related]
44. TP53 germline and somatic mutations in a patient with fibrolamellar hepatocellular carcinoma. Andrade RC; de Lima MAFD; de Faria PAS; Vargas FR Fam Cancer; 2018 Jan; 17(1):119-122. PubMed ID: 28477317 [TBL] [Abstract][Full Text] [Related]
45. Current management of hepatocellular cancer. Rampone B; Schiavone B; Confuorto G Curr Oncol Rep; 2010 May; 12(3):186-92. PubMed ID: 20425078 [TBL] [Abstract][Full Text] [Related]
46. Fibrolamellar carcinoma of the liver: a distinct entity within the hepatocellular tumors. A review. Vecchio FM Appl Pathol; 1988; 6(2):139-48. PubMed ID: 2839216 [TBL] [Abstract][Full Text] [Related]
47. Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Li S; Mao M Cancer Lett; 2013 Nov; 340(2):247-53. PubMed ID: 23063663 [TBL] [Abstract][Full Text] [Related]
48. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma? Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852 [TBL] [Abstract][Full Text] [Related]
49. Combined Hepatocellular-Cholangiocarcinoma: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma. Kim DH; Choi SH; Kim DW; Lee SS; Lim YS; Kim SY; Kim HJ; Kim JH; Byun JH J Magn Reson Imaging; 2021 Jun; 53(6):1803-1812. PubMed ID: 33565208 [TBL] [Abstract][Full Text] [Related]
50. Prostate-specific membrane antigen expression in hepatocellular carcinoma, cholangiocarcinoma, and liver cirrhosis. Chen LX; Zou SJ; Li D; Zhou JY; Cheng ZT; Zhao J; Zhu YL; Kuang D; Zhu XH World J Gastroenterol; 2020 Dec; 26(48):7664-7678. PubMed ID: 33505143 [TBL] [Abstract][Full Text] [Related]
51. Clinicopathological features and prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgery. Lee SD; Park SJ; Han SS; Kim SH; Kim YK; Lee SA; Ko YH; Hong EK Hepatobiliary Pancreat Dis Int; 2014 Dec; 13(6):594-601. PubMed ID: 25475861 [TBL] [Abstract][Full Text] [Related]
52. MicroRNAs in hepatocellular carcinoma: carcinogenesis, progression, and therapeutic target. Hung CH; Chiu YC; Chen CH; Hu TH Biomed Res Int; 2014; 2014():486407. PubMed ID: 24800233 [TBL] [Abstract][Full Text] [Related]
54. Hepatocellular carcinoma from the view of gastroenterologist/hepatologist. Petr U; Petr H Klin Onkol; 2020; 33(Supplementum 3):34-44. PubMed ID: 33213164 [TBL] [Abstract][Full Text] [Related]